# TOL-463 Phase 2 Study for Vaginitis

> **NCT02866227** · PHASE2 · COMPLETED · sponsor: **Toltec Pharmaceuticals, LLC** · enrollment: 106 (actual)

## Conditions studied

- Bacterial Vaginosis
- Vulvovaginal Candidiasis

## Interventions

- **DRUG:** TOL-463
- **DRUG:** TOL-463

## Key facts

- **NCT ID:** NCT02866227
- **Lead sponsor:** Toltec Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-15
- **Primary completion:** 2017-06-10
- **Final completion:** 2017-06-10
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866227, "TOL-463 Phase 2 Study for Vaginitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02866227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*